A Phase III study of radiation therapy versus sorafenib to treat unresectable hepatocellular carcinoma led by the National Cancer Centre of Singapore, along with the Singapore Clinical Research Institute and Sirtex Medical, has completed enrollment for an Asia-wide effort.